United States Pharmacopeia - India Profile
Key Indicators
- Authorised Capital ₹ 50.00 Cr
as on 12-07-2024
- Paid Up Capital ₹ 36.39 Cr
as on 12-07-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 9.40%
(FY 2022)
- Profit 33.76%
(FY 2022)
- Ebitda 28.08%
(FY 2022)
- Net Worth -17.14%
(FY 2022)
- Total Assets -16.97%
(FY 2022)
About United States Pharmacopeia - India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 50.00 Cr and a paid-up capital of Rs 36.39 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at United States Pharmacopeia - India Private Limited India is Rohit Gr as COMPANY SECRETARY. Venkat Koduru, Amanda Cowley, Girish Kapur, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230TG2005PTC046362
- Company No.
046362
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 May 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at United States Pharmacopeia - India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rohit Gr | Company Secretary | 16-Jan-2013 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amanda Cowley  | Director | 20-Dec-2017 | Current |
Venkat Koduru  | Director | 24-Jul-2014 | Current |
| Girish Kapur | Director | 31-Dec-2019 | Current |
| Mrunal Jaywant | Director | 03-Sep-2021 | Current |
Financial of United States Pharmacopeia - India.
United States Pharmacopeia - India Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 9.4% increase. The company also saw a substantial improvement in profitability, with a 33.76% increase in profit. The company's net worth observed a substantial decline by a decrease of 17.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of United States Pharmacopeia - India?
In 2022, United States Pharmacopeia - India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at United States Pharmacopeia - India?
Unlock and access historical data on people associated with United States Pharmacopeia - India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of United States Pharmacopeia - India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped United States Pharmacopeia - India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
